oncology business unit. since his retirement, he now serves on multiple boards in the united states. including somerset regional health center, the ada industry advisory board, the concord cancer foundation. it is a privilege to have john with us today. there is a saying we have, and that is the patient never gets it wrong. the speaker you will certainly enjoy as well is heather falwell are. she is a graduate of american university and washington, d.c., and she now enjoys traveling to exotic locations around the world with her husband, jeff. she lives in maryland with her husband, son, and two rescued cats. her hobbies include vegetable gardens, sewing, and home decorating. in the spring of 2012, she was diagnosed with stage four cancer following a craniotomy. her story is compelling. you will certainly enjoy all that she has to share with you. it is my privilege to also share, you will be addressed today by several biomedical researchers and clinicians who while not in this room, has sent their message to y

this year marked the 50th anniversary of the american society of oncology.hich, in 1964, seven people got together to discuss cancer innovations and how it could move forward. move forward to 2014. membersore than 35,000 and is one of the largest organizations to demonstrate cancer innovations. now, not only is co emphasizing its large membership, but it's emphasizing .ew cancer innovations and the new and innovative technologies we are using and that show our patients can survive and live longer. will see theey years showing significant advances in overall cancer survivorship. the american cancer society just this year reported that there was a 20% decline in cancer deaths over the last two decades. it means that 1,340,400 deaths were eliminated and therefore, these people survived. in 1960 four, there were fewer than 3 million cancer survivors. in 2014, there are more than 14 million people in the united states living and having survived cancer. time.s an extraordinary it's very important that we continue the innovation in cancer research. meeting, at the

oncology business unit. since his retirement, he now serves on multiple boards in the united states. including somerset regional health center, the ada industry advisory board, the concord cancer foundation. it is a privilege to have john with us today. there is a saying we have, and that is the patient never gets it wrong. the speaker you will certainly enjoy as well is heather falwell are. she is a graduate of american university and washington, d.c., and she now enjoys traveling to exotic locations around the world with her husband, jeff. she lives in maryland with her husband, son, and two rescued cats. her hobbies include vegetable gardens, sewing, and home decorating. in the spring of 2012, she was diagnosed with stage four cancer following a craniotomy. her story is compelling. you will certainly enjoy all that she has to share with you. it is my privilege to also share , you will be addressed today by several biomedical researchers and clinicians who while not in this room, has sent their message to

he recommended a uclaology ko-- ucla oncology that kbinld drugs. then he had roy's tumor genome sequenced. based on the results, roy has now taken part in a clinical trial involving another front in cancer treatment. >> that's the t cell. that is the cancer cell. >> it is called immunotherapy. he is not the only one working on it. he was anxious to show us why oncologists believe it's a promising field. a time lapsed demonstration of how t cells which immune system's naturally produce can attack cancer cells. >> this is a cell that is actually gobbling up the dancer cell. this cell will grows in size and the cell will decrease in size. so there is the t cell gobbling it up. there is the cancer cell. >> that's amazing. >> so you're watching cancer cells die here. >> correct. >> you find the t cells and you're able to isolate them. is the idea then that you no he they do the job. you can come out and grow them proliferate them and put them back into the body? >> exactly. >> even though it's been two years now since david roy's original diagnosis, he'

you know there is a lot of excitement about immuno oncology. merck is on the forefront with the first drug of its kind approved in the united states. we have innovative drugs in hiv, osteoporosis, cardiovascular. it's an exciting time to be at merck. we don't think a big merger will help us bring those kinds of drugs to the patients who need them faster. >> ken frazier, ceo of merck thank you for joining us. >> thanks for having me, meg. >>> i'll pick it up there from meg terrell. thank you for that. sticking with us health as the kind of top of the broadcast theme. get the chicken soup ready it is shaping up to be a rough flu season. bertha coombs has more. >> i haven't gotten my shot yet but i am headed across the street to get one soon. the cdc says it is early yet and have seen elevated flu in texas and georgia and alabama and the south. they think this could be a bad season because of the severity of the flu strain they are seeing already. this year the h 3 n 2 is most prevalent. in the last three times we have seen it over the last decade

it happened during my 4 years in a special unit focus on oncology was developed and someone was hired to run it. and what a scary place because it seemed as if what we have to offer for most of the patients who came into that part of the hospital were very toxic poisonous substances. many of the individuals who had various types of tumors responded quite poorly. it certainly did not seem to me at that point if somebody was interested in having to bring together science and medicine that they had gotten together very clearly in this space. maybe hard to imagine but at that point, the underlying model we take for granted that cancer is the disease of the genome had not really been appreciated. going back to the early part of the 20th entry suggesting that was something about the chromosomes. seeing that emerge as a actionable, unifying approach to this disease that will lead us in the direction of what we now embrace as a remarkable resolution of targeted therapy that would've been really impossible for myself or others to imagine happening during her lifetime's. it has been a breathtak

. >> while the oncology world may cringe when he boasts as he is prone to do, patients see him differentlythe established community doesn't like false hope, but if you have a terminal disease like i do you want some hope. >> david roy was diagnosed two years ago with stage four met static pancreatic cancer. he was given four months to live and told to settle his affairs. he recommended a ucla oncologist who devised an unusual therapy. then he had roy's tumor genome sequenced. roy is taking part in a clinical trial involving another front in cancer treatment. >> that is the cancer cell. >> it's called immunotherapy. he is not the only one working on it but he was anxious to show us why oncologists believe it is a promising field. a time lapsed demonstration of how t-cells which our immune systems naturally produce can attack cancer cells. >> this is a cell gobbling up the cancer cell. this will decrease in cell. here is the t cell gobbling it up. here is the cancer cell. >> that's amazing. >> you are literally watching cancer cells die here. >> correct. >> you find these t cells and able to

next step, they're going to use this platform to sort of look ahead and they're already looking at oncology with the bone metastheses. at this point the fda approved the uterine fibroids and the bone metastheses. he created a phase three clinical trial for tremor, not just parkinson's but the motor disorder. go inside inside tech and show a guy trembling so much, his tremors are so severe he can't drink a cup of water. after the treatment, one treatment, the guy is like drink, drink, handwriting suddenly is neat. it's a game changer. it's going to change people's lives. >> what i don't get is that this has been around since 1999. i know they actually debuted in israel. >> it's an israeli company, the first procedure was done in 2004 for the fibroids. >> this is 2014. >> i know, i don't know why it's not on front page news everywhere. honestly, before you folks gave me this wonderful assignment, i hadn't heard of it and i've been in the field of health for 25 years. that's why i'm thrilled you asked me to look it up. this could change people's lives. i know two women who had hysterectomies,

they're already looking at oncology. at this point, the fda has approved the uterine fibroid and the bone me it's a seize. they show this video. people should go to insighttec, google it. they're showing a guy whose tremors are so severe he can't drink a glass of water. after the treatment, drink, drink, handwriting is suddenly neat. it's a game changer. >> what i don't get is this has been around since 1999. i know they actually debuted in israel. >> yes, an israel company. first procedure in 2004 for the fibroids. >> this is 2014. >> i know. i don't know why it's not on front-page news everywhere. honestly, before you folks gave me this wonderful assignment, i'd never heard of it, and i've been in the health field for 25 years. it should be talked about. that's why i'm so thrilled you asked me to look it up. this could change people's lives. i know two women who had hysterectomies. six weeks' recovery. that's six weeks off work. >> they might not have had to have the hysterectomy if they could have e blated that tumor.

anderson on the oncology expert advice and be able to ingest data clinically in a community setting, not just in the walls of m.d. anderson. and how that system being taught by the world experts. what would they do essentially a second opinion? that would then give advice to the treating physician that is what the world experts would do and it would be the clinical trials you should consider and so on. will reduce -- once they get implemented. informations age of and is in fact is going to be on a practical level as most impactful and reducing the burden of cancer in our country. critics do you worry about this, dr. collins? if so, what can you do? >> we do not have a good track record of taking research and finding how they integrate into the standard of care across the country. a few years ago, somebody look at that timetable and concluded 20 years and that is unacceptable. there aren't good news aspects of the way things are going. ron talked about some related to the cancer field. the best art of the story is the patient's are no longer comfortable sitting back and waiting for so

we're also very pleased there are other drugs such as oncology drugs that can help patients. we are about patients and treetding patients. my whole career is about that so i'm thrilled there are other drugs to help patients and we think it is the center focus of hodgkins lymphoma and combining them well and you will see in the future. >> do you think, though, with the market's reaction is it missing in some ways the opportunity that it has? you're testing in it a lot of other indications. >> yeah. we think that it has a really great opportunity to be a blockbuster drug in front line therapy. front line therapy is a same for 38 years and it's four cytotoxic drugs and one especially of lung toxicity an trying to get rid of that and redefine front line therapy. and include this and not the other and the data for the lead-in trial is extraordinary. and we have a huge amount of doctor support here. the doctors, we have been running around the halls and doctors are congratulating us on the data so we're really excited. you know, this conference is about doctors and presenting data.

i want to see the president do well, but it took him six years to give a major public policy oncology and income inequality. when we finally got there, this is the defining issue of our time. and so you would think that he would've been quiet for six years? six years? he wouldn't have said anything? i know the truth. and the truth is that king would have challenged him on poverty and militarism and not being disrespectful, he would've been like me, i would hope. when the president is wrong, you correct the president and that's how you do everything. respect, protest, correct. that is how they have to deal with them. but it will be interesting on this issue of militarism. and we cannot zone our way into world a these. i have said that 50 years after his death, what did he see? racism, poverty and militarism. and we have work that has to be done and i hope this book will allow you to see the journey that he walked the last mile of the way and how when he tried to tell his truth everyone turned against him and honor him and he kept getting up everyday speaking his truth anyway and how he

. >> gupta: while the oncology world may cringe when he boasts, as he's prone to do, patients see himavid roy: the established community doesn't like false hope. but if you have a terminal disease, like i do, you want some hope. >> gupta: david roy was diagnosed two years ago with stage four metastatic pancreatic cancer. he was given four and a half months to live and told to settle his affairs. he called dr. soon-shiong, whom he had met on a plane years before. soon-shiong recommended a ucla oncologist who devised an unusual therapy that combined abraxane with other cancer drugs. then, soon-shiong had roy's tumor genome sequenced. based on those results, roy is now taking part in a clinical trial involving another front in cancer treatment. >> soon-shiong: that's the t- cell and that's the cancer cell. >> gupta: it's called immunotherapy. soon-shiong is not the only one working on it, but he was anxious to show us why oncologists believe it's a promising field-- a time-lapse demonstration of how t-cells, which our immune systems naturally produce, can attack cancer cells. >> soon-shi

so that combined with immuno oncology is hope for patients.ext decade is going to be the decade of molecular biology with information technologies. when people talk about the future of health care, we are on the dawn of great things happening. this is just the beginning. it's incredibly exciting but the beginning. >> so much more to discuss we have to leave it there. bob hugin, thank you so much. >> thanks for having me. >> scott, back to you guys. >> thanks so much for bringing us that exclusive interview. again the stock is a good performer. it's leading the s&p today, all-time high. you like merck, you like pfizer. >> i like celgene, gilley adbut throw out two more, amgen and biogen. when you look at pipelines that's what we're talking about terms of growth and the future. the pipeline for somebody like am again they have -- amgen in the mid-teens of late stage in the pipeline. the potential we're talking about and the valuation level, biogen and amgen are low closer towards big pharma than biotech. >> want to jump back to our headquarters.

. >> in my 30 years as an oncology nurse, there have been advances that have gone from being totally un_curable to one_year survival, now two years and years of survival. i think we have the knowledge now to continue with the research that we have been doing to make cancer a disease that very few people die of. >> therapy in cancer is a revolution __ now, targeted therapy requires development of diagnostics, as well as targeted treatment. >> we need better data. we need personal data about everyone's genetic makeup, so we can use that information literally in the individual war on cancer for each patient. it is critical that we get patients involved. also leveraging things like electronic health records __ to help us see what has been tried, and what could be tried. >> we needed __ need to get survival rate to a better place. >> so, you have heard from a number of people today. now it is your turn. what we'll would like to do is invite you to address your questions to any of our panelists. the floor is open for questions. if you could, go to the microphone in the center of the aisle.

it happened during my four years where a special unit focused on oncology was developed and run it. to as a medical student and intern nd resident it was a scary place because it seemed as if what we had to offer for most of into tients who came particular part of the hospital , poisonous xic ubstances and many people with solid tumors responded quite poorly. it didn't seem to me as somebody ho was interested in bringing together science and medicine that they had gotten together very clearly in this space. hard to imagine but at that point the underlying model we now take for granted that is a disease of the genome had not really been going ated and we had back to the early part of the about thery something chromosomes involved. an ng that emerge as actionable unifying approach to this disease that would lead us what we now ion of embrace as this remarkable -- se hraourgs in target revolution in targeted therapies imagine e been hard to in our lifetime. so it has been a breathtaking ride. i think when the war on cancer was initially declared in didn't have 0's we the tools or insig

i think that is one of the other four areas that merck is focused on with oncology agents like pembroe to look at those and a host of other cancers as well as combining them with existing agents. i think you're going to see a lot more in this field from companies like merck that have already been focused there. but i think merck will, you know, ratchet up its activity in the field as well. >> okay. all right. thanks, barbara. appreciate it. >> thank you. bye. >>> and the dow is ever so close to crossing the 18,000 mark. another major milestone. the industrials first crossed the 17,000 mark back on july 3rd of this year. crude oil on that day closed at $104 a barrel. it's down close to 40% since then. here to dazzle us with more dow facts and figures or our stats man dominic chu. they sate stats geek in -- do you want to be a geek? >> i can be a geek sometimes. if we're in business news, we're all a bit of a geek at some point in time. let's look at some of the big dow winners and losers. since july 3rd, a lot's happened in the course of market history here. between 17,000 and 18,000 s